Codexis, Inc. rose 21.1% on Friday, November 13, 2026, on 2,498,148 shares, 2.7 times its average daily volume. Headlines around the move:
Codexis, Inc. (CDXS:NASDAQ) closed at $1.16 on November 13, 2026, up 21.07% on the day. The stock trades 61.1% below its 52-week high of $2.98 and 28.9% above its 52-week low of $0.900. Over the past year, it lost 29.7%. Codexis, Inc. is part of the Basic Industries sector (Major Chemicals).
In 252 trading sessions since November 13, 2025, CDXS closed higher on 117 days (46%). Its best day was March 12, 2026 (+34.65%) and its worst was July 24, 2026 (-25.63%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 2 times.
Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also improves the pharmaceuticals companies manufacturing productivity and efficiency, as well as helps in outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. Further, the company develops biocatalysts for use in the fine chemicals market, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in t...
Find more stocks like CDXS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.